Tango Therapeutics, Inc. reported a net loss of $45.5 million for the first quarter of 2026, compared to a net loss of $39.9 million for the same period in 2025. The company's total operating expenses increased to $48.8 million from $47.9 million year-over-year, driven primarily by a rise in general and administrative expenses, which rose to $15.2 million from $11.5 million. Research and development expenses decreased slightly to $33.5 million from $36.4 million, reflecting a reduction in costs associated with certain clinical programs, including the discontinuation of the TNG908 trial.
In terms of revenue, Tango Therapeutics did not recognize any collaboration revenue in the first quarter of 2026, a decline from $5.4 million in the prior year. This decrease is attributed to the conclusion of the research term of the collaboration agreement with Gilead Sciences, which resulted in the recognition of all remaining deferred revenue in 2025. The company’s cash, cash equivalents, and marketable securities totaled $379.8 million as of March 31, 2026, providing a runway to fund operations into 2028.
Strategically, Tango Therapeutics is focusing on the clinical development of its PRMT5 inhibitors, vopimetostat and TNG456, targeting genetically defined cancers. The company has entered into clinical trial collaboration agreements with Revolution Medicines and Erasca, Inc. to evaluate vopimetostat in combination with other therapies. The company plans to provide updates on clinical data and its path to registration for vopimetostat in 2026.
Operationally, Tango Therapeutics has seen fluctuations in its employee headcount and engagement metrics, with a focus on advancing its clinical programs. The company anticipates continued significant operating losses as it invests in research and development, regulatory approvals, and commercialization efforts. The outlook remains cautious, with the need for substantial additional funding to support ongoing operations and product development, as the company has yet to generate revenue from product sales.
About Tango Therapeutics, Inc.
Tango Therapeutics is a precision oncology company focused on developing targeted cancer therapies by exploiting genetic vulnerabilities such as tumor suppressor gene loss. Its pipeline includes novel small molecules targeting PRMT5 and CoREST, aimed at genetically defined patient populations. The company leverages advanced target discovery platforms, collaborates with industry partners, and relies on third-party manufacturing to deliver innovative treatments for cancers with high unmet medical needs.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.